Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 1;95(1139):20220470.
doi: 10.1259/bjr.20220470. Epub 2022 Aug 10.

Lung shunt fraction quantification methods in radioembolization: What you need to know

Pooya Torkian  1 , Ranjan Ragulojan  1 , Gregory J Woodhead  2 , Donna D'Souza  1 , Siobhan Flanagan  1 , Jafar Golzarian  1 , Shamar Young  2
Affiliations
Review

Lung shunt fraction quantification methods in radioembolization: What you need to know

Pooya Torkian et al. Br J Radiol. .

Abstract

In some patients undergoing radioembolization, lung toxicity is a limiting factor when calculating their dose. At the same time, it is known that the lung shunt fraction (LSF) is overestimated by the mapping exam. Furthermore, there are multiple methods to measure LSF. Planar measurement is both the most commonly utilized and easiest to perform, however new dosimetry software provides the ability to use more advanced 3D techniques. This paper reviews the different LSF calculation methods and elucidates the available data comparing the techniques, clinical relevance, and dose calculation.

PubMed Disclaimer

References

    1. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. . Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151: 1155–63. doi: 10.1053/j.gastro.2016.08.029 - DOI - PMC - PubMed
    1. Gordon AC, Gabr A, Riaz A, Uddin OM, Abouchaleh N, Ali R, et al. . Radioembolization super survivors: extended survival in non-operative hepatocellular carcinoma. Cardiovasc Intervent Radiol 2018; 41: 1557–65. doi: 10.1007/s00270-018-2008-y - DOI - PMC - PubMed
    1. Wehrenberg-Klee E, Gandhi RT, Ganguli S. Patient selection and clinical outcomes of Y90 in hepatocellular carcinoma. Tech Vasc Interv Radiol 2019; 22: 70–73. doi: 10.1053/j.tvir.2019.02.006 - DOI - PubMed
    1. Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. . Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6: 17–29. doi: 10.1016/S2468-1253(20)30290-9 - DOI - PubMed
    1. Allred JD, Niedbala J, Mikell JK, Owen D, Frey KA, Dewaraja YK. The value of 99mtc-MAA SPECT/CT for lung shunt estimation in 90y radioembolization: a phantom and patient study. EJNMMI Res 2018; 8(1. doi: 10.1186/s13550-018-0402-8 - DOI - PMC - PubMed

Substances